AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Fierce Biotech6d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Investing6d
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Its experimental candidates, amycretin and CagriSema, aim to improve weight loss outcomes through a dual mechanism. However, recent disappointing trial results for CagriSema have weighed on Novo ...
NBC DFW6d
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
You need that to a certain degree, but it's also the quality of the weight loss, the durability of response, the ability to switch between mechanisms," he said via video call. Petrelintide is ...
NBC Washington6d
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate, as the two firms seek to ...